Cancer drug hope raises Genmab's spirits after legal defeat

Biotech firm Genmab and partner Abbvie have delivered promising topline data from their shared drug hope epcoritamab, a bone marrow cancer treatment. An important validation for Genmab, assesses an analyst, as the company recently lost an important legal battle.
Photo: Joost Melis / Genmab / PR
Photo: Joost Melis / Genmab / PR
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen

The show must go on, as the saying goes, which is also true for the biotech sector.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading